Role of co-expression of estrogen receptor beta and Ki67 in prostate adenocarcinoma

Nornazirah Azizan, Firdaus Hayati, Nur Maya Sabrina Tizen, Wirda Indah Farouk, Noraidah Masir

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: To evaluate the expression of estrogen receptor (ER)-beta and Ki67 in prostate cancer and study their relationship. Materials and Methods: We analyzed 101 cases of prostate adenocarcinoma diagnosed from January 2011 to June 2015 in 100 patients. Immunohistochemical staining of ER-beta and Ki67 was analyzed according to Gleason score categorized into prognostic groups of 1 to 5. Double-immunofluorescent staining of ER-beta and Ki67 was performed in a total of 20 cases to study the co-expression and the relationship between these markers within the same tumor. Results: A total of 53 of 101 cases (52.5%) were positive for ER-beta expression. There was a positive correlation whereby a high percentage of ER-beta expression was seen in the higher prognostic groups (groups 4 and 5; p=0.007). High Ki67 expression was observed in the higher prognostic group, whereas low Ki67 or negative expression was found in the lower prognostic group (p<0.001). The majority of cases evaluated with double-immunofluorescent staining (14/20) showed co-expression of ER-beta and Ki67 at the individual cell level. Conclusions: ER-beta and Ki67 are independent tumor markers in high prognostic groups. Hence, co-expression of ER-beta and Ki67 indicates a more aggressive tumor with a poorer prognosis.

Original languageEnglish
Pages (from-to)232-237
Number of pages6
JournalInvestigative and Clinical Urology
Volume59
Issue number4
DOIs
Publication statusPublished - 1 Jul 2018

Fingerprint

Estrogen Receptor beta
Prostate
Adenocarcinoma
Staining and Labeling
Neoplasm Grading
Tumor Biomarkers
Neoplasms
Prostatic Neoplasms

Keywords

  • Estrogen receptor beta
  • Ki-67 antigen
  • Neoplasm grading
  • Prostate neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

Role of co-expression of estrogen receptor beta and Ki67 in prostate adenocarcinoma. / Azizan, Nornazirah; Hayati, Firdaus; Tizen, Nur Maya Sabrina; Farouk, Wirda Indah; Masir, Noraidah.

In: Investigative and Clinical Urology, Vol. 59, No. 4, 01.07.2018, p. 232-237.

Research output: Contribution to journalArticle

Azizan, Nornazirah ; Hayati, Firdaus ; Tizen, Nur Maya Sabrina ; Farouk, Wirda Indah ; Masir, Noraidah. / Role of co-expression of estrogen receptor beta and Ki67 in prostate adenocarcinoma. In: Investigative and Clinical Urology. 2018 ; Vol. 59, No. 4. pp. 232-237.
@article{85234d13f6e24e24a3f3e98bb9d31891,
title = "Role of co-expression of estrogen receptor beta and Ki67 in prostate adenocarcinoma",
abstract = "Purpose: To evaluate the expression of estrogen receptor (ER)-beta and Ki67 in prostate cancer and study their relationship. Materials and Methods: We analyzed 101 cases of prostate adenocarcinoma diagnosed from January 2011 to June 2015 in 100 patients. Immunohistochemical staining of ER-beta and Ki67 was analyzed according to Gleason score categorized into prognostic groups of 1 to 5. Double-immunofluorescent staining of ER-beta and Ki67 was performed in a total of 20 cases to study the co-expression and the relationship between these markers within the same tumor. Results: A total of 53 of 101 cases (52.5{\%}) were positive for ER-beta expression. There was a positive correlation whereby a high percentage of ER-beta expression was seen in the higher prognostic groups (groups 4 and 5; p=0.007). High Ki67 expression was observed in the higher prognostic group, whereas low Ki67 or negative expression was found in the lower prognostic group (p<0.001). The majority of cases evaluated with double-immunofluorescent staining (14/20) showed co-expression of ER-beta and Ki67 at the individual cell level. Conclusions: ER-beta and Ki67 are independent tumor markers in high prognostic groups. Hence, co-expression of ER-beta and Ki67 indicates a more aggressive tumor with a poorer prognosis.",
keywords = "Estrogen receptor beta, Ki-67 antigen, Neoplasm grading, Prostate neoplasms",
author = "Nornazirah Azizan and Firdaus Hayati and Tizen, {Nur Maya Sabrina} and Farouk, {Wirda Indah} and Noraidah Masir",
year = "2018",
month = "7",
day = "1",
doi = "10.4111/icu.2018.59.4.232",
language = "English",
volume = "59",
pages = "232--237",
journal = "Investigative and Clinical Urology",
issn = "2466-0493",
publisher = "Korean Urological Association",
number = "4",

}

TY - JOUR

T1 - Role of co-expression of estrogen receptor beta and Ki67 in prostate adenocarcinoma

AU - Azizan, Nornazirah

AU - Hayati, Firdaus

AU - Tizen, Nur Maya Sabrina

AU - Farouk, Wirda Indah

AU - Masir, Noraidah

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Purpose: To evaluate the expression of estrogen receptor (ER)-beta and Ki67 in prostate cancer and study their relationship. Materials and Methods: We analyzed 101 cases of prostate adenocarcinoma diagnosed from January 2011 to June 2015 in 100 patients. Immunohistochemical staining of ER-beta and Ki67 was analyzed according to Gleason score categorized into prognostic groups of 1 to 5. Double-immunofluorescent staining of ER-beta and Ki67 was performed in a total of 20 cases to study the co-expression and the relationship between these markers within the same tumor. Results: A total of 53 of 101 cases (52.5%) were positive for ER-beta expression. There was a positive correlation whereby a high percentage of ER-beta expression was seen in the higher prognostic groups (groups 4 and 5; p=0.007). High Ki67 expression was observed in the higher prognostic group, whereas low Ki67 or negative expression was found in the lower prognostic group (p<0.001). The majority of cases evaluated with double-immunofluorescent staining (14/20) showed co-expression of ER-beta and Ki67 at the individual cell level. Conclusions: ER-beta and Ki67 are independent tumor markers in high prognostic groups. Hence, co-expression of ER-beta and Ki67 indicates a more aggressive tumor with a poorer prognosis.

AB - Purpose: To evaluate the expression of estrogen receptor (ER)-beta and Ki67 in prostate cancer and study their relationship. Materials and Methods: We analyzed 101 cases of prostate adenocarcinoma diagnosed from January 2011 to June 2015 in 100 patients. Immunohistochemical staining of ER-beta and Ki67 was analyzed according to Gleason score categorized into prognostic groups of 1 to 5. Double-immunofluorescent staining of ER-beta and Ki67 was performed in a total of 20 cases to study the co-expression and the relationship between these markers within the same tumor. Results: A total of 53 of 101 cases (52.5%) were positive for ER-beta expression. There was a positive correlation whereby a high percentage of ER-beta expression was seen in the higher prognostic groups (groups 4 and 5; p=0.007). High Ki67 expression was observed in the higher prognostic group, whereas low Ki67 or negative expression was found in the lower prognostic group (p<0.001). The majority of cases evaluated with double-immunofluorescent staining (14/20) showed co-expression of ER-beta and Ki67 at the individual cell level. Conclusions: ER-beta and Ki67 are independent tumor markers in high prognostic groups. Hence, co-expression of ER-beta and Ki67 indicates a more aggressive tumor with a poorer prognosis.

KW - Estrogen receptor beta

KW - Ki-67 antigen

KW - Neoplasm grading

KW - Prostate neoplasms

UR - http://www.scopus.com/inward/record.url?scp=85049480326&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049480326&partnerID=8YFLogxK

U2 - 10.4111/icu.2018.59.4.232

DO - 10.4111/icu.2018.59.4.232

M3 - Article

C2 - 29984337

AN - SCOPUS:85049480326

VL - 59

SP - 232

EP - 237

JO - Investigative and Clinical Urology

JF - Investigative and Clinical Urology

SN - 2466-0493

IS - 4

ER -